Zymeworks Inc.
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of multifunctional biopharmaceuticals to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial performance after the market closes on August 1, 2024. Following the announcement, management will host a conference call and webcast at 4:30 pm ET on August 1, 2024 to discuss the financial performance and provide a company update.
The event will be webcast live and dial-in details and a webcast replay will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a clinical-stage global biotechnology company committed to the discovery, development, and commercialization of novel multi-functional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people suffering from hard-to-treat cancers and other diseases. The company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely design and develop highly differentiated antibody-based therapeutic candidates. Zymeworks designed and developed zanidatamab, a bispecific antibody targeted to HER2, using its proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), each granting them exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is currently being evaluated in multiple global clinical trials as a first-in-class treatment for patients with HER2-expressing cancers. The Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of zanidatamab for the treatment of previously treated unresectable locally advanced or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted priority review. The BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. If approved, zanidatamab will be the first HER2-targeted therapy approved specifically for BTC in the U.S. and China. Building on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics, Zymeworks is rapidly advancing a rich pipeline of product candidates in areas of unmet medical need with many novel targets. In addition to its wholly owned pipeline, Zymeworks’ therapeutic platform has been further leveraged through strategic partnerships with global biopharmaceutical companies. For more information about Zymeworks, please visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
The story continues
contact address:
Investor Inquiries:
Srinar Inamdar
Director of Investor Relations
(604) 678-1388
email address
Investor Relations
For media enquiries please contact:
Diana Papov
Senior Director of Corporate Communications
(604) 678-1388
email address
inquiry
